Targeted antibody offers hope for painful blistering skin condition
NCT ID NCT04563923
Summary
This study tested whether adding an experimental antibody called avdoralimab to standard steroid creams could better control bullous pemphigoid, a painful blistering skin disease that mainly affects older adults. Fifteen hospitalized patients in France received either the antibody plus steroids or steroids alone to see which approach led to complete skin healing. The goal was to find a more targeted treatment that might work better than existing options while avoiding certain side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHM, Hôpital Nord
Marseille, Bouches du rhône, 13000, France
-
APHM, Timone
Marseille, Bouche Du Rhône, 13005, France
-
CHU Montpellier, Dermatologie
Montpellier, Herault, 34005, France
-
CHU de Nice- Dermatologie
Nice, Alpes-Maritimes, 06200, France
Conditions
Explore the condition pages connected to this study.